https://www.selleckchem.com/pr....oducts/cx-4945-silmi
Recent reports demonstrate the occurrence of IE in SCD patients and show important alterations in the hematopoietic and erythroid niches, both in SCD patients and in the humanized Townes SCD mouse model. This implies that therapeutic strategies initially designed to improve red cell survival in the circulation of SCD patients would also positively impact erythropoiesis and bone marrow cellularity. IE is the major cause of anemia in β-thalassemia patients, and it is generally surmised that it contributes little to anemia of
Like
Comment
Share
